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Neuroimaging has been extensively used to study brain structure and function in indi-
viduals with attention deficit/hyperactivity disorder (ADHD) and autism spectrum
disorder (ASD) over the past decades. Two of the main shortcomings of the
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neuroimaging literature of these disorders are the small sample sizes employed and
the heterogeneity of methods used. In 2013 and 2014, the ENIGMA-ADHD and
ENIGMA-ASD working groups were respectively, founded with a common goal to
address these limitations. Here, we provide a narrative review of the thus far com-
pleted and still ongoing projects of these working groups. Due to an implicitly hierar-
chical psychiatric diagnostic classification system, the fields of ADHD and ASD have
developed largely in isolation, despite the considerable overlap in the occurrence of
the disorders. The collaboration between the ENIGMA-ADHD and -ASD working
groups seeks to bring the neuroimaging efforts of the two disorders closer together.
The outcomes of case–control studies of subcortical and cortical structures showed
that subcortical volumes are similarly affected in ASD and ADHD, albeit with small
effect sizes. Cortical analyses identified unique differences in each disorder, but also
considerable overlap between the two, specifically in cortical thickness. Ongoing
work is examining alternative research questions, such as brain laterality, prediction
of case–control status, and anatomical heterogeneity. In brief, great strides have been
made toward fulfilling the aims of the ENIGMA collaborations, while new ideas and
follow-up analyses continue that include more imaging modalities (diffusion MRI and
resting-state functional MRI), collaborations with other large databases, and samples
with dual diagnoses.
K E YWORD S
ADHD, ASD, cortex, ENIGMA, neuroimaging, subcortical volumes
1 | INTRODUCTION
Two of the most frequently diagnosed neurodevelopmental disorders
are attention deficit/hyperactivity disorder (ADHD) and autism spec-
trum disorder (ASD), which occur in 5–7% and 1–2.8% of children,
respectively (Baird et al., 2006; Faraone et al., 2015; Thomas, Sanders,
Doust, Beller, & Glasziou, 2015; Xu et al., 2018). Both disorders may
persist across the lifespan (Nylander, Holmqvist, Gustafson, &
Gillberg, 2013). ADHD is characterized by age-inappropriate,
impairing and persisting levels of inattention and/or hyperactivity/
impulsivity (American Psychiatric Association, 2013), while ASD is
characterized by impaired communication, social interaction skills, and
repetitive and restricted behavior (American Psychiatric Associa-
tion, 2013). Up until 2013, when the fifth edition of the Diagnostic
and Statistical Manual for Mental Disorders (DSM-5) was published,
the presence of an ASD diagnosis excluded a diagnosis of ADHD.
Hence, dual diagnosis of both disorders did not officially exist. The
research fields for both disorders therefore developed largely in isola-
tion. However, the current diagnostic guidelines of the DSM-5 allow
for their dual diagnosis, which has led to the rise of a new field of
research studying the overlap between ADHD and ASD. Research in
recent years has shown that ADHD is the most common comorbidity
in children with ASD (Joshi et al., 2017); 40–70% of children with
ASD have comorbid ADHD (Joshi et al., 2017; Kaat, Gadow, &
Lecavalier, 2013; Salazar et al., 2015). Of children with ADHD, 15–
25% show clinically relevant ASD symptoms (Cooper, Martin, Langley,
Hamshere, & Thapar, 2014; Kotte et al., 2013), and 12% meet criteria
for an ASD diagnosis (Jensen & Steinhausen, 2015). A large-scale twin
study also demonstrated that patients with ASD have a much higher
chance of having ADHD than the general population (OR = 22.33)
(Ronald, Simonoff, Kuntsi, Asherson, & Plomin, 2008). Another twin
study indicated that children diagnosed with one of the two disorders
often show features of the other, even in the absence of a full comor-
bid diagnosis (Ghirardi et al., 2018).
In addition to the frequent co-occurrence of both disorders in the
population, ADHD and ASD partly overlap in their pathophysiology
and phenomenology in socialization and communication domains (e.g.,
[Antshel, Zhang-James, & Faraone, 2013]). Latent class analyses of
both clinical and community-based samples dissociated four distinct
patient groups—ADHD, ADHD + ASD, ASD + ADHD, and ASD—with
the middle two patient groups showing symptoms of both disorders,
with either one dominating the clinical picture (van der Meer
et al., 2012). These findings gave rise to the hypothesis that ADHD
and ASD may be viewed as different manifestations of the same over-
arching disorder, with each diagnosis representing the extreme end of
a complex multivariate trait and with most clinical cases presenting
various combinations of ADHD and ASD symptoms (Antshel, Zhang-
James, Wagner, Ledesma, & Faraone, 2016). Even without hypothe-
sizing about a single, overarching disorder, it is well accepted that core
features of both ADHD and ASD—in particular inattention and social
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deficits—overlap, and that partly, but not fully, overlapping patterns
are found in cognitive and behavioral traits associated with ADHD
and ASD traits (Rommelse, Geurts, Franke, Buitelaar, & Har-
tman, 2011; Truedsson, Bohlin, & Wåhlstedt, 2015; van der Meer
et al., 2017). Such hypothesis would lead to the abandonment of
viewing ADHD and ASD as opposing phenotypes (e.g., Mayes, Cal-
houn, Mayes, & Molitoris, 2012).
Given the common background between these two disorders, the
work done in the ENIGMA ADHD and ASD working groups may be
used to further our understanding of both the unique and common
neurobiological aspects of both disorders.
1.1 | The genetic background of ADHD and ASD
Further evidence for commonalities between ADHD and ASD comes
from genetic research. Genetically, ADHD and ASD are both complex
disorders, influenced by environmental and genetic susceptibility fac-
tors. Results from family, twin and adoption studies converge to sug-
gest that both ADHD and ASD have a high heritability (75 and 90%,
respectively; Faraone & Larsson, 2019; Freitag, 2007). Both common
and rare genetic variants contribute to this heritability (Satterstrom
et al., 2019), and part of this heritability is shared by the two disorders
(Faraone & Larsson, 2019; Rommelse, Franke, Geurts, Hartman, &
Buitelaar, 2010; Ronald & Hoekstra, 2011). Considering common
genetic variants, large-scale genome-wide association studies (GWAS)
meta-analyses confirmed that ADHD and ASD are significantly geneti-
cally correlated (37%; Lee et al., 2019). Similarly, in the general popu-
lation, the genetic backgrounds of ADHD and ASD were also found to
be partly shared throughout childhood and adolescence (Stergiakouli
et al., 2017). Rare variants with strong effect sizes directly explain
ASD or ADHD in a relatively small number of people only, though
many such variants are known to contribute to each disorder or both
(e.g., Satterstrom et al., 2019). Many of the genes hit by such rare risk
variants are also likely to converge on biological processes
(Bourgeron, 2015) that are shared by ASD and ADHD (and other neu-
rodevelopmental disorders; Cristino et al., 2014; Schork et al., 2019).
These processes include those involved in chromatin remodeling and
transcription, protein synthesis and degradation, synaptic receptors
and cell adhesion molecules, and scaffolding proteins (Luo, Zhang,
Jiang, & Brouwer, 2018).
1.2 | Neuroimaging across the lifespan in ADHD
and ASD before the founding of ENIGMA-ADHD and
ENIGMA-ASD
In the past decades, many neuroimaging studies have investigated the
structure and function of the brains of individuals with ADHD and
ASD. Within the ADHD literature, most studies showed structural
case–control differences across a wide variety of brain regions, in chil-
dren but also in adults with ADHD (Faraone et al., 2015; Franke
et al., 2018). Further, ADHD symptom ratings in the population were
found to be negatively associated with, for example, thickness of the
cortex (Mous et al., 2014; Shaw et al., 2011). A total of five meta-ana-
lyses based on case–control studies have tried to identify common
differences in brain structure associated with ADHD, based on case–
control studies (Ellison-Wright, Ellison-Wright, & Bullmore, 2008;
Frodl & Skokauskas, 2012; Nakao, Radua, Rubia, & Mataix-Cols, 2011;
Norman et al., 2016; Valera, Faraone, Murray, & Seidman, 2007). The
most consistent results across those meta-analyses were reduced vol-
umes of (parts of) the striatum in patients compared to controls. Two
of those five studies reported that striatal structural differences
between individuals with ADHD and controls decreased with increas-
ing age, and that stimulant treatment was associated with normalizing
effects on the brain volume differences (Frodl & Skokauskas, 2012;
Nakao et al., 2011). This work highlighted the role of the striatum in
the ADHD pathology. Limitations of these meta-analyses included the
limited ability to investigate the role of individual variables on the
identified brain differences, such as comorbidities, medication use, but
also age, and the inability to look at lifespan trajectories. Such lifespan
trajectories are of interest in ADHD because longitudinal studies of
brain volume suggest a delay of brain maturation for individuals with
ADHD, but of yet unknown significance for remittance and persis-
tence of ADHD into adulthood (Shaw et al., 2007, 2011).
Much of the research done on ASD has focused on the role of
subcortical brain abnormalities (Amaral, Schumann, & Nordahl, 2008).
Both larger (Turner, Greenspan, & van Erp, 2016) and smaller
(Sussman et al., 2015) volumes of striatal structures have been
reported, while higher average intracranial volume, total gray matter,
and cortical thickness have also previously been found in ASD
(Fombonne, Rogé, Claverie, Courty, & Frémolle, 1999; Haar, Berman,
Behrmann, & Dinstein, 2016), with more specific cortical effects in
the frontal and temporal lobes (Foster et al., 2015; Zielinski
et al., 2014). Altered frontal and striatal volumes and disrupted
fronto-striatal connectivity are key components in the executive func-
tion deficit theory of ASD (Di Martino et al., 2011; Langen et al., 2012).
On the other hand, abnormal amygdala volumes, specifically in child-
hood, may be related to the social theories of ASD (Baron-Cohen
et al., 2000). However, the neuroimaging literature is not consistent
as far as the direction and effect size of these morphometric brain dif-
ferences go (Nickl-Jockschat et al., 2012; Stanfield et al., 2008). The
introduction of the ABIDE consortium—a publicly available data set of
MRI data from 13 existing cohorts—has not managed to reduce much
of the pre-existing heterogeneity, as analyses (Haar et al., 2016)
showed only very small local associations of ASD with brain mor-
phometry, perhaps questioning the presence of structural differences
in ASD altogether.
Several small scale studies have examined differences and overlap
in brain structure between ADHD and ASD, reporting overlapping
structural brain alterations in the temporal and parietal areas (Brieber
et al., 2007), inferior frontal cortex (Geurts, Ridderinkhof, &
Scholte, 2013), cerebellum, corpus callosum (Dougherty, Evans,
Myers, Moore, & Michael, 2016), as well as white matter (Ameis
et al., 2016). A study of white matter organization in children with
ADHD, ASD, and controls observed transdiagnostic associations
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between continuous measures of ASD symptoms and inattention (but
not total ADHD symptoms) and indexes of white matter organization,
particularly in the corpus callosum (Aoki et al., 2017). An analysis of
intrinsic connectivity in cases with ADHD, ASD, and controls found
evidence for both shared and distinct underlying mechanisms at the
large-scale network level. Shared connectivity alterations were found
in the precuneus, whereas ADHD-specific increases in degree central-
ity were assessed in right striatum/pallidum, and ASD-related
increases in degree centrality in bilateral temporolimbic areas (Di
Martino et al., 2013). Overall, there is a distinct lack of well-powered
cross-disorder studies that include both cases with ADHD and ASD
(Rommelse, Buitelaar, & Hartman, 2017). Furthermore, the few exis-
ting studies focused solely on children, leaving the overlap between
ADHD and ASD over the lifespan almost completely unknown.
Taken together, the pre-existing literature on brain imaging in
ADHD and ASD still shows considerable gaps as well as opportunities
for improvement. Two of the main shortcomings remain to be the
small sample sizes and the wide heterogeneity in the methodology
used, both of which have likely contributed to the difficulty in repli-
cating imaging findings. Opportunities to remedy at least some of
these shortcomings are facilitated by the ENIGMA consortium. Over
the past decade, this consortium has provided a platform for combin-
ing genetic and brain imaging datasets (Adams et al., 2016; Hibar
et al., 2015, 2017; Stein et al., 2012), while using unified
preprocessing and analysis pipelines to substantially increase sample
sizes and decrease methodological heterogeneity as well as allow
direct comparison between different disorders such as ADHD and
ASD. Working groups for ADHD and ASD research were founded
under ENIGMA's umbrella in 2013 and 2014, respectively, with the
following aims: (a) reduce methodological heterogeneity in neuroimag-
ing studies that might cause differences in findings across studies; (b)
increase power to identify (new) characteristics of individuals with
ADHD and ASD; (c) cross-sectionally map the lifespan trajectory of
brain characteristics of ADHD and ASD; and (d) combine expertise
and join forces from around the world on brain research for ADHD
and ASD to boost our understanding of the brain in ADHD and ASD.
Both working groups' initial projects focused on subcortical brain vol-
ume and cortical thickness and surface area analyses.
2 | KEY FINDINGS FROM THE ENIGMA-
ADHD AND ENIGMA-ASD STUDIES:
SUBCORTICAL AND CORTICAL MEASURES
In the ENIGMA-ADHD's first project, the volumes of subcortical
structures including nucleus accumbens, amygdala, caudate nucleus,
globus pallidus, hippocampus, thalamus, putamen, and also the total
intracranial volume (ICV) were compared between cases with ADHD
and controls. These regional brain volumes were segmented based on
protocols provided by ENIGMA using FreeSurfer software. All partici-
pating sites segmented their raw data and quality checked of these
segmentations locally using protocols provided by ENIGMA. Detailed
instructions for analysis and quality control are found on the ENIGMA
website (http://enigma.ini.usc.edu/protocols/imaging-protocols/). The
resulting outputs were sent by each site to the coordinator of
ENIGMA-ADHD. Analyses were performed on data collected at 23
sites, that included a total of 1,713 cases with ADHD and 1,529 con-
trols, with an age range of 4–63 years of age. A cross-sectional mega-
analysis examined case–control differences within the whole sample,
and also separately in children (<15 years), adolescents (15–21 years),
and adults (>21 years). A linear mixed model was run with age, sex,
and ICV as fixed variables and site as a random variable. Results for
the total sample showed significant but small differences in the total
volume of nucleus accumbens (Cohen's d = −0.15), amygdala (d =
−0.19), caudate nucleus (d = −0.11), hippocampus (d = −0.11), puta-
men (d = −0.14), and ICV (d = −0.10), where the subjects with ADHD
had smaller volumes as compared to controls (Hoogman et al., 2017).
A follow-up meta-analysis confirmed the mega-analysis results. When
age groups were considered, case–control differences were only sig-
nificant in children. No effects of psychostimulant use or of present
comorbidities were found, nor were there any detectable effects of
ADHD severity (symptom counts). However, the statistical power for
these latter analyses was lower as the availability of these variables in
the varied at 25–50% of the total sample.
The second main analysis of the working group covered the
cortex, where cortical thickness and surface area were calculated
on 34 region segmentations from the Desikan-Killiany atlas
(Desikan et al., 2006; Hoogman et al., 2019). Since completion of
its subcortical project, ENIGMA-ADHD had grown to 36 sites
including 4,180 individuals—2,246 with ADHD and 1,934 control
subjects which were included in the cortical project. Results
showed, on average, lower surface area in frontal, cingulate, and
temporal regions in the analysis of children with ADHD versus con-
trols, with the largest case–control effect sizes in the youngest
group of children. The largest effect was found for total surface
area (d = −0.21). Lower cortical thickness values were found for
the fusiform gyrus and temporal pole in children with ADHD com-
pared to controls. Neither surface area nor thickness differences
were found in the adolescent and adult groups. In collaboration
with the Generation-R study (White et al., 2018), a pediatric popu-
lation study in Rotterdam, The Netherlands, ENIGMA-ADHD
found that symptoms of inattention were negatively associated
with total surface area, and the surface area of two regions that
had shown significant case–control differences in the initial
ENIGMA-ADHD analyses. In other words, case–control effects in
the caudal middle frontal gyrus and middle temporal gyrus were
also detected in a nonclinical population sample of children
10 years of age. Similar trends were seen for other regions, such as
in one of the ENIGMA-ADHD samples (n = 506), called
NeuroIMAGE (von Rhein et al., 2015), significant regions from the
ENIGMA-ADHD analysis were compared between cases, their
unaffected siblings and unrelated typically developing controls to
investigate familial effects. Compared to controls, the unaffected
siblings had lower on average surface area values for caudal middle
frontal gyrus, lateral orbital frontal gyrus, superior frontal gyrus,
and total surface area. However, mean values did not differ
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significantly from their affected siblings (Hoogman et al., 2019).
Since siblings share 50% of their genes, these data suggest that
familial factors, genes and/or shared environment, may play a role
in the cortical differences observed in ADHD.
In the ENIGMA-ASD working group, findings from the subcor-
tical volume and cortical thickness/surface area analyses were pub-
lished in a joint manuscript (van Rooij et al., 2018). The
preprocessing and analysis pipelines followed were identical to
those used in the ADHD working group analyses. A total of 52 sites
were included in this primary analysis, with a total of 1,571 cases
with ASD and 1,651 controls. The cross-sectional ASD mega-analy-
sis was performed over the entire age range. Small but significant
deficits were found in the subcortical volumes of the pallidum (d =
−0.08), putamen (d = −0.10), amygdala (d = −0.08), and nucleus
accumbens (d = −0.13). Cortical analysis showed no detectable dif-
ferences in regional and total surface areas. However, cases with
ASD showed greater cortical thickness in frontal brain areas, and
lower cortical thickness in temporal/occipital brain areas (d = −0.21
to d = 0.2). The effects of age were uniform over all subcortical and
cortical findings as all showed a distinct peak difference between
cases with ASD and controls around adolescence, but a normaliza-
tion in adults.
3 | OVERLAP AND DIFFERENCES
BETWEEN THE CASE–CONTROL STUDIES OF
ADHD AND ASD FOR SUBCORTICAL AND
CORTICAL MEASURES
When examining the main results from the cortical and subcortical
analyses of the ENIGMA-ADHD and ASD working groups, we can
readily observe several common and distinct patterns (Hoogman
et al., 2017; Hoogman et al., 2019; van Rooij et al., 2018). The two
cohorts were strikingly similar in the subcortical volume analysis, as
both disorders show comparable decreases in putamen, amygdala and
nucleus accumbens volumes when compared to controls (see Figure 1
and Table 1). Cortical thickness measures also showed some
comparable effects between the ADHD and ASD publications as both
disorders were associated with lower thickness in the temporal lobes,
yet only ASD showed increased cortical thickness, specifically in the
frontal lobe (see Figure 2). The strongest observed effect from the
cortical analyses in ADHD was in surface area, as cases showed a sig-
nificant overall smaller surface area, compared to controls (Hoogman
et al., 2019). This is in stark contrast to the ASD results, where no sur-
face area affects were observed. The limitation of these analyses is
the lack of full ASD symptomatology/diagnosis coverage in the ADHD
cohorts and vice versa.
Based on these patterns of overlapping and unique effects in
the separate analyses of the ADHD and ASD working groups, the
next logical step was to repeat these analyses on the combined data
from the two working groups. One of the main advantages of a
mega-analytic approach based on common analysis pipelines in the
different ENIGMA working groups is the comparability of the data.
In a recent cross-disorder analysis, we combined structural brain
data from the ENIGMA-ADHD, ENIGMA obsessive compulsive dis-
orders (OCD), and ENIGMA-ASD working groups in order to investi-
gate shared and unique effects among the three disorders (Boedhoe
et al., 2019). The analysis included 2,271 subjects with ADHD,
1,771 with ASD, 2,323 with OCD, and 5,827 controls, and was sub-
divided by age into children (<12 years), adolescents (12–17 years),
and adults (18 years and older). Findings showed strongest overlap
between ASD and ADHD effects in childhood, where both cases
with ADHD and ASD showed overall lower volumes in subcortical
areas, as well as lower cortical thickness in precentral and temporal
lobes. However, effect sizes were small, and most did not survive
correction for multiple comparisons. When comparing cases among
ADHD, ASD and OCD, we saw the largest difference in total ICV:
children with ASD showed a higher average ICV, compared both to
controls and with cases with ADHD or OCD. Hippocampal volumes
were smaller in children with ADHD as compared with children with
OCD, and smaller in adults with OCD and ASD as compared with
controls, although neither this difference survived multiple compari-
son correction. As for cortical thickness, adults with ADHD had
lower cortical thickness in orbitofrontal, inferior frontal and
F IGURE 1 Cohen's d effect sizes for the subcortical volumes and total intracranial volume (ICV) for both ADHD and ASD cohorts as
compared to controls. Figures taken and adapted from Hoogman et al. (2017) and van Rooij et al. (2018)
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cingulate areas, compared with adults with ASD, OCD and healthy
controls. Taken together, these analyses indicated that there are
unique cortical features in each disorder, but also considerable over-
lap between the two disorders, specifically when considering corti-
cal thickness. Subcortical volumes were similarly affected in both
ASD and ADHD, although the effects sizes over all age bins
remained quite small.
4 | SECONDARY PROJECTS WITHIN
ENIGMA-ADHD AND ENIGMA-ASD
In the spirit of ENIGMA, researchers within the collaboration are
encouraged to perform additional analyses on the collected data
aiming to address alternative research questions, or to use the net-
work to test new analytic strategies and methods. For ENIGMA-
TABLE 1 Summary of findings of the (sub)cortical analyses in ENIGMA-ADHD and ENIGMA-ASD
Working
group Results of subcortical analyses
Results of cortical thickness
analyses







intracranial volume in all
samples combined and when
stratified only significant in
children with ADHD.




-thinner fusiform gyrus and
temporal pole in all samples
combined and when
stratified into age groups,
only significant in children
with ADHD.
-no differences in adolescents
and adults with ADHD
-smaller surface areas for:
superior frontal gyrus, lateral
orbitofrontal cortex,
posterior cingulate cortex,
caudal middle frontal gyrus,
middle temporal gyrus, and
total surface area in children
with ADHD.
-no differences in adolescents
and adults with ADHD
-siblings of individuals with
ADHD showed smaller
surface area for caudal
middle frontal gyrus,
superior frontal gyrus and
total surface area.
- children in the general
population also showed
higher rates of symptoms of
inattention to correlate with
surface area of the caudal
middle frontal gyrus, the




Cases with ASD showed
smaller volume of the
nucleus accumbens,
amygdala, pallidum, and
putamen and a bigger
intracranial volume.
Cases with ASD showed
greater cortical thickness in
frontal brain areas (including
the frontal pole), and lower
cortical thickness in
temporal/occipital brain
areas (including the fusiform
gyrus).
Cortical analysis showed no
detectable differences in
regional and total surface
areas.
The effects of age were
uniform over all subcortical
and cortical findings—all
showed a distinct peak
difference between cases
with ASD and controls
around adolescence, and
normalization in adults.
Note: Results that are underlined are overlapping results with the same direction of the effect for both disorders. Results in italic indicate overlapping
regions affected for both disorders but with opposite effects.
F IGURE 2 Cohen's d effect sizes for the cortical measures for both ADHD and ASD cohorts as compared to their controls. Figures taken and
adapted from Hoogman et al. (2019) and van Rooij et al. (2018). Only the Freesurfer segmentations which showed a significant effect in either
group are depicted, this means that only results of the thickness analyses are depicted here, as none of the surface area results were significant in
the ASD analyses
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ADHD and ENIGMA-ASD, there are four projects with overlapping
objectives. These are projects on laterality, machine learning, stratifi-
cation, and virtual histology. Within ENIGMA-ADHD, an additional
project focused on the cerebellum was also conducted. These projects
are at various stages, and have been either published after peer
review, posted as preprint without peer review on bioRxiv and
awaiting peer review results, or are still in the process of being ana-
lyzed and written up. Table 2 outlines an overview each projects.
4.1 | Laterality analysis in ENIGMA-ADHD and
ENIGMA-ASD
The laterality projects in the ADHD and ASD working groups aim to
identify changes of left–right structural brain asymmetry in the
affected populations. In contrast to previous findings in ADHD liter-
ature, the ENIGMA-ADHD laterality study showed no evidence for
asymmetry in the caudate nucleus. All the other brain asymmetry
analyses for case–control differences in children, adolescents and
adults, showed no significant results that survived multiple compari-
son correction (Postema, Hoogman, et al., 2020). Alterations in the
degree of cortical thickness asymmetry in frontal, cingulate, and
inferior temporal areas were observed in the ENIGMA-ASD
laterality study (Postema, van Rooij, et al., 2019), with subjects with
ASD showing reduced asymmetry in all areas. The only exception to
this was leftward putamen asymmetry, which was significantly
increased in ASD.
4.2 | Machine learning results in ENIGMA-ADHD
and ENIGMA-ASD
Both subcortical and cortical data were used to predict case–control
status through machine learning within ENIGMA-ADHD (Zhang-
James et al., 2019). Using support vector machine, random forests, K-
Nearest Neighbors, and gradient boosting classifiers, the model was
estimated in 85% of the sample while the remaining 15% of the sam-
ple was used to test the model's accuracy. Results showed a statisti-
cally significant discrimination between ADHD and control subjects.
However, prediction accuracies were relatively low at 67% for adults
and 66% for children. The most informative structures unsurprisingly
overlapped with those structures that showed significant case–control
differences in the main analysis of the ENIGMA-ADHD data: ICV, sur-
face area, and some subcortical volumes (Hoogman et al., 2017;
Hoogman et al., 2019). It is encouraging to see that by combining all
brain data in the machine learning analysis, instead of examining iso-
lated case–control differences, the adult group did show significant
case–control differences. A model based on child data significantly
predicted ADHD status in the adult sample and vice-versa, suggesting
that the structural MRI differences detected by the machine learning
algorithm were similar in children and adults. In order to increase the
prediction, larger sample sizes or the addition of other data modalities
(e.g., diffusion MRI, resting state functional MRI) might be required.
Alternatively, this may also be achieved by integrating machine learn-
ing results with other cohorts, like ASD.
The same machine learning strategy has been applied in an ongo-
ing study within the ASD working group. The analyses gave mostly
similar results in terms of predictive accuracy, with a preliminary low
accuracy of around 60%. However, a striking result occurred when
merging the ENIGMA-ADHD and ASD cohorts in the training set. Pre-
liminary results indicate that the predictive accuracy on the diagnosis
of ASD in the prediction set was significantly higher when the training
set includes also the ENIGMA-ADHD data. This may be partly due to
the fact that in this case, the number of controls is doubled, however,
it may also be due to the fact that learning examples of a third diag-
nostic category (in this case ADHD) may help the algorithm dissociate
more clearly between the other two (ASD and controls). These prelim-
inary findings demonstrate that, even though the effect sizes of brain
differences on a group level are small, there is still much information
in these morphometric features that advanced algorithms can use to
dissociate cases from controls. Additionally, it highlights the impor-
tance of collaboration between scientists working on different disor-
ders in neurodevelopmental research in general, and within the
ENIGMA consortium in particular.
4.3 | Stratification analyses in ENIGMA-ADHD and
ENIGMA-ASD
An important observation from the primary structural brain analyses
published by both the ENIGMA-ADHD and -ASD working groups
(Hoogman et al., 2017; Hoogman et al., 2019; van Rooij et al., 2018)
was the high within-group variance in any given brain metric, which
makes it hard to detect between-group differences. We hypothesize
that, on a population level, different neuroanatomical profiles may
exist, which would correspond to more homogeneous neuroanatomi-
cal subgroups. An important secondary goal of ENIGMA-ADHD and
ENIGMA-ASD is therefore to stratify the structural brain data into
subgroups, and investigate how this influences case–control compari-
sons and whether these subgroups have a unique neurobiological
profile.
In order to investigate potential stratifications in the subcortical
volumes, we employed a two-step analysis. First, the subcortical vol-
umes for all subjects were entered in an exploratory factor analysis
(EFA), which is used to summarize the nine subcortical volumes into a
couple of underlying factors. Next, these factors were used in a Com-
munity Detection clustering analysis, to see if there were specific sub-
groups within the patient and control populations that differ in their
subcortical brain profile (Li et al., 2019). In an ongoing study, similar
analyses are being carried out for both the ENIGMA-ADHD and ASD
datasets.
The EFA results showed that variations in subcortical volumes
can be reduced to three main factors, in males aligning with the
striatum, limbic system, and thalamus. This factor structure was
based on both cases and controls, and was stable between the
ADHD and ASD cohorts. There were some differences between
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TABLE 2 Overview of the published and ongoing work by the ENIGMA-ADHD and ASD working groups




differences in participants with
attention deficit hyperactivity
disorder in children and adults: a
cross-sectional mega-analysis.




Cortical and subcortical brain
morphometry differences
between patients with autism
spectrum disorder and healthy
individuals across the lifespan:
Results from the ENIGMA ASD
Working Group.




A multicohort, longitudinal study
of cerebellar development in
attention deficit hyperactivity
disorder.




Brain imaging of the cortex in
ADHD: A coordinated analysis
of large-scale clinical and
population-based samples.






asymmetry in autism spectrum
disorder in a study of 54
datasets.




Machine learning classification of
attention-deficit/hyperactivity
disorder using structural MRI
data.






Subcortical brain volume, regional
cortical thickness and cortical
surface area across attention-
deficit/hyperactivity disorder
(ADHD), autism spectrum
disorder (ASD), and obsessive–
compulsive disorder (OCD).
ADHD & ASD (and
OCD)
Accepted for publication at AM.
J.Psy, published on bioRxiv
https://doi.org/10.1101/
673012
Li et al. (2019) Characterizing neuroanatomic
heterogeneity in people with
and without ADHD based on
subcortical brain volumes.






An ENIGMA consortium analysis
of structural brain asymmetries
in attention-deficit/
hyperactivity disorder in 39
datasets.






Virtual histology of cortical
thickness reveals shared
neurobiology underlying six
psychiatric disorders: A meta-
analysis of 148 cohorts from the
ENIGMA Consortium.
ADHD & ASD (and
other working
groups)





based feature extraction using
cross-disorder datasets.
ADHD and ASD In preparation NA
Li et al. (2020) Dissecting the heterogeneous
subcortical brain volume of
autism spectrum disorder (ASD)
using community detection.
ASD In preparation NA
Abbreviation: NA, not available.
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males and females, and among female children, adolescents, and
adults. Community detection analysis indicated that the cohorts
can subsequently be stratified into four separate profiles, each
corresponding to a unique loading pattern on the striatum, limbic
system, and thalamus factors. Once more, these observed commu-
nities were stable between the ADHD and ASD analyses, and the
distribution between the communities was comparable between
cases and controls. This allowed us to then look at case–control
differences within each of the four communities. The effect sizes
of the case–control comparisons for both ADHD and ASD were
significantly higher within the four distinct communities than they
were over the entire cohort. This study also indicated that the
community structure may change over the lifespan, with one com-
munity disappearing in adulthood. This shift suggests that neuroan-
atomical diversity may decrease with age. As of now, both the
ADHD and ASD cohorts had too few females to conduct suffi-
ciently powered community detection analyses accounting for sex,
as sex differences in neuroanatomical organization are a highly
important topic within ADHD and ASD research. We hope that
with further growth of the ENIGMA cohorts, these analyses may
soon become feasible.
Although all the findings discussed here are still preliminary at the
time of writing, all results support our main hypothesis, which is that
it is likely that there are relatively more homogeneous subgroups
within the population based on brain structure, and that taking into
account these subgroups can significantly increase the effect sizes of
our case–control analyses.
4.4 | Virtual histology analyses for ENIGMA-
ADHD and ENIGMA-ASD and four other disease
working groups
Neuroimaging studies have observed robust differences in cerebral
cortical morphology (thickness and surface area) within patients
across different psychiatric disorders (Thompson et al., 2020).
However, the neurobiological changes underlying these macro-
scopic structural differences in the cerebral cortex are not well
understood. To gain further insights into the profiles of group dif-
ferences in the ENIGMA-ADHD and ENIGMA-ASD cohorts, we
employed a virtual histology approach (Patel et al., 2018; Shin
et al., 2018). This entails relating inter-regional profiles of gene
expression from the Allen Human Brain Atlas with inter-regional
profiles in differences of cortical thickness across the 34 regions of
the Desikan-Killiany atlas (Desikan et al., 2006; Hawrylycz
et al., 2012). Virtual histology may allow us to make inferences
about which cell types (e.g., pyramidal, interneuron, astrocytes,
microglia, and oligodendrocyte) are enriched in regions that show
large group differences in cortical thickness. The aim for virtual his-
tology projects is to employ this approach in six psychiatric disor-
ders (ADHD, ASD, bipolar disorder, OCD, major depressive
disorder, and schizophrenia) in order to characterize shared and/or
unique neurobiology of group differences in cortical thickness
across these disorders; a total of 12,006 cases and 14,842 controls
are contributing to this project, which is currently ongoing.
4.5 | Cerebellum analysis in ENIGMA-ADHD
One additional project in ENIGMA-ADHD aimed to investigate the
specific neuroanatomy of the cerebellum in ADHD. A collaborative
initiative of four cohorts from the working group (Shaw et al., 2018)
segmented various regions in the cerebellum to identify growth tra-
jectories in these regions for cases and controls. In a sample of 1,656
subjects (patients and controls), diagnostic differences in growth in
the corpus medullare (cerebellar white matter) emerged. Specifically,
cases with ADHD showed slower growth in early childhood compared
to the typically developing group and a reversed effect in late
childhood.
5 | STRENGTHS, CHALLENGES, AND
LIMITATIONS OF ENIGMA-ADHD AND
ENIGMA-ASD
The main strength of the ENIGMA consortium in the field of ADHD
and ASD brain imaging has been the sharing of existing data, which
consequently further unifies the experience and expertise of the field.
By going beyond meta-analyses and really sharing individual test sta-
tistics, we were able to run more sophisticated analyses than would
have otherwise been possible.
The ENIGMA working groups have clear data management,
writing, and publication guidelines described in a memorandum of
understanding which is signed by all participating members. This
ensures transparency among all working group members in both the
process and the outcome of all new analyses. The open nature of
the working groups has a positive snowballing effect of new sites
and PI's joining regularly, thus resulting in a larger body of data for
each new analysis. The ENIGMA policy on secondary proposals
dictates that all working group members can submit secondary pro-
posals, which has led to many interesting and important contribu-
tions which were spearheaded by different members of the
ENIGMA-ADHD and ASD working groups. As highlighted previ-
ously, another strength is the sharing of open access protocols for
imaging analyses, developed by dedicated methods working groups
within the ENIGMA consortium (http://enigma.ini.usc.edu/
protocols/imaging-protocols/). These detailed protocols include
brain segmentation into defined anatomical regions using
FreeSurfer 5.3 and quality control procedures, and help remove var-
iance that would come from using different methods. In general, the
statistical models that are used to calculate case–control differences
are also similar among working groups. Mixed linear models using
the nlme package in R are implemented with age, sex and case–con-
trol status as fixed variables and “site” as a random factor. Varying
among working groups, interactions of the fixed factors are some-
times added to the model to acquire a better model fit. This varies
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among the working groups. Depending on the brain measures ana-
lyzed, additional covariates accounting for global head size are
added. In subcortical volume projects intra cranial volume was
added as covariate, and in cortical surface area projects, analyses
were performed with and without total surface area as covariate.
Even with these efforts, several challenges and limitations remain.
One of the key difficulties that the working groups face is the nature
of the data itself. Legacy data, which refers to the pre-existing data
from previous studies and publications, inherently lacks harmonization
of data collection and phenotyping protocols, and is additionally less
accessible for follow up data acquisition than in new studies. It has at
times proven difficult to repeatedly organize new analyses which
require access to the locally stored raw imaging data, especially at
sites where the authors of the original publications have left and
moved to new positions. Similarly, demographic and phenotypic data
from the many different sites were acquired in different years across
several decades, using different tools and methods, with different
goals in mind. This led to considerable heterogeneity in, for instance,
the symptom ratings within cohorts, as well as inconsistent assess-
ment of comorbidities. In ENIGMA-ADHD, we currently have infor-
mation available for 55% of the patients on ADHD symptom rating
scales. For 58% of the patients there is information about com-
orbidities and for 44% and 66% of the patients we have data available
for lifetime stimulant use and current stimulant use, respectively. For
ENIGMA-ASD, the Autism Diagnostic Observation Scale (ADOS) is
available for 27% of the cohort, as well as 15% for comorbidity infor-
mation and 49% for current medication use. The historical focus of
existing publications on a categorical (case, control) rather than
dimensional phenotyping approach limits the depth of phenotype
associations available in ENIGMA-ADHD and ASD. Another example
of the difficulties that we face can be found in the change from DSM-
IV to DSM-5. Before DSM-5 was published, ADHD and ASD could
not be diagnosed simultaneously. This led many older samples to
forgo acquiring ADHD/ASD comorbidity data, as this was thought to
be superfluous at the time. Given that there likely was some comor-
bidity of ASD symptoms in the ADHD cohort and vice versa, this may
have increased the overlap in structural brain alterations between the
two cohorts. Re-contacting the original patients or even researchers
of these legacy samples is often not feasible, limiting depth and fidel-
ity of the available phenotypic data in the ENIGMA-ADHD and ASD
cohorts.
6 | FOLLOW-UP OF ENIGMA-ADHD AND
ENIGMA-ASD: RESULTS BEYOND THE
COLLABORATION
Work from the ENIGMA-ADHD and ENIGMA-ASD groups has
inspired various follow-up analyses. The ENIGMA-ADHD working
group discovered volume reductions in patients with ADHD in ICV
and volumes of subcortical regions. However, how such alterations
contribute to the disease phenotype remains largely unknown. As
both ADHD and brain volumes have a high heritability, it has been
suggested that genetic variants underlying ADHD pathophysiology
may also influence brain volume variation. A recent study investigated
the genetic covariance between ADHD risk and the brain volumes
implicated in ADHD. On a global, genome-wide level a significant neg-
ative genetic correlation between ADHD and ICV was found, meaning
that variants linked to smaller ICV were associated with increased
ADHD risk (Klein et al., 2019). This resembles the phenotypic obser-
vation that individuals with ADHD have smaller ICV relative to control
subjects. On the single variant and gene-wide levels, several signifi-
cant loci were associated with both ADHD risk and brain volume
(Klein et al., 2019). Similar genetic overlap analyses revealed that cor-
tical structure variation is genetically correlated with ADHD (Grasby
et al., 2020). More specifically, a significant negative genetic correla-
tion between ADHD and global surface area, a brain phenotype highly
correlated with ICV, was found (Grasby et al., 2020). This type of inte-
grated genome-wide analyses can help develop new hypotheses
about biological mechanisms by which brain structure alterations may
be involved in ADHD disease etiology. The genetic correlation
between ADHD and ICV showed some specificity to this disorder, as
it was not found in studies of other psychiatric disorders, such as
schizophrenia (Adams et al., 2016; Franke et al., 2016), major depres-
sive disorder (Wigmore et al., 2017), or ASD (Grove et al., 2019), using
similar methods. A related analysis by Radonijc et al. (this issue)
showed that, across several disorders investigated by ENIGMA work-
ing groups, those that showed greater case–control structural brain
differences also showed more similarities in their common genetic
variant architectures.
In analyses using the case–control standardized mean differences
for subcortical regions from the ADHD-ENIGMA analyses, Hess and
coworkers (Hess, Akutagava-Martins, Patak, Glatt, & Faraone, 2018)
reported that gene expression profiles (Allen Human Brain Atlas) for
three biological pathways were significantly correlated with ADHD-
associated volumetric reductions: apoptosis, oxidative stress, and
autophagy. These correlations were strong and significant in children
with ADHD, but not in adults. In a subsequent analysis that also
included cortical data from ENIGMA-ADHD, the same group found
that ADHD-associated volumetric reductions were associated with
apoptosis, autophagy, and neurodevelopment gene pathways and
with regional abundances of dopaminergic neurons, astrocytes, oligo-
dendrocytes, and neural progenitor cells (Hess, Radonjic, Patak, Glatt,
& Faraone, 2019). These data suggest that the selective brain region
vulnerability seen in ADHD may be due to differences in the cellular
composition and constitutive gene expression between regions, which
do and do not show ADHD-associated volumetric changes.
7 | THE FUTURE FOR COLLABORATIVE
NEUROIMAGING IN ADHD AND ASD
Great strides have been made toward fulfilling the aims of the
ENIGMA collaboration, especially for increasing the power of neuro-
imaging studies in ADHD and ASD. The published work of these col-
laborations includes by far the biggest sample sizes in the field of
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neuroimaging for the respective disorders. First, this has made it pos-
sible to identify robust case–control differences with stringent
methods (such as split half validation, Mackey et al., 2018). Second,
although we need to be aware of the limitations of cross-sectional
data, the wide age range of our samples (ADHD: 4–63 years, ASD: 2–
64 years) allows the examination of case–control differences across
the life-span. Together with the large sample sizes that facilitate pow-
erful age-group analysis, we can formulate more specific hypotheses
about the development of brain differences across the life-span. Third,
the additional projects derived from these collaborations are strong
examples that our aim of combining expertise to boost our under-
standing of ADHD and ASD in relation to the brain has been met and
is continuously replenished with new ideas. Not only within the col-
laborative group itself, but also other researchers have also been
inspired to come up with subsequent research questions to generate
even more knowledge about brain differences that are associated
with the disorders, coming from related fields (Hess et al., 2018; Klein
et al., 2019). While the first articles of additional analyses are now
being published, much work is still ongoing, and more cohorts are still
joining our working groups. We therefore expect more output from
these initiatives. Finally, we aimed to reduce methodological hetero-
geneity by making the preprocessing and analysis pipeline used in
ENIGMA-ADHD and ASD public, as well as many of the analysis
results per site. This gives unprecedented insights into the amount
and range of variance of outcomes between studies that for the first
time establishes a clear baseline against which new samples can easily
be compared.
7.1 | Collecting additional data within our working
groups
Our future work will be dedicated to performing new analyses and
including additional data. The ENIGMA-ADHD and -ASD groups are
currently working on the analysis of structural connectivity data from
diffusion tensor imaging (DTI). With the DTI projects we will perform
similar analyses as for brain volume but move beyond testing for iso-
lated brain regions. Here we can, again, make use of processing pipe-
lines provided by ENIGMA, which have already been successfully
used (Favre et al., 2019; van Velzen et al., 2019; Villalón-Reina
et al., 2019). Within the ENIGMA-ASD cohort, resting state fMRI data
are also being analyzed, pooled together with existing datasets such
as the EU-AIMS cohort, parcellated into standard functional regions
of interest, and used for a graph-theory analysis of the functional
brain (dis)connectivity. The addition of DTI and resting state fMRI
data to the existing structural brain data in the ENIGMA-ADHD and
ASD working groups is an important step toward true multimodal
imaging data integration, one of the most important long-term goals
of these ENIGMA working groups. All our current findings, as well as
the literature on ADHD and ASD, overwhelmingly indicate that neural
alterations are visible across all available imaging modalities. There
currently exist no large-scale dataset where structural, functional, and
connectivity data are combined, so it is largely unclear how findings
among these different modalities are interrelated. To move toward a
more complete neurobiological model of ADHD and ASD, multimodal
data integration will be key.
To learn more about the overlap and differences between ADHD
and ASD, we want to focus on samples that have allowed dual diagno-
sis of both disorders. As was discussed in the strengths, challenges
and limitations section, most of the current studies into ADHD/ASD
excluded the other disorder for data collection. Adding a third group
with a true combined diagnosis will strengthen the cross-disorder
analysis of ADHD and ASD immensely, and will aid the investigation
of how the genetic and neural correlates of ADHD and ASD interact,
and how this influences the development of the disease phenotype
over the lifespan.
7.2 | Collaborating with other consortia
As was mentioned in this article, ADHD and ASD may be seen as dif-
ferent manifestations of a broader phenotype. This view can be fur-
ther extended to include multiple neurodevelopmental disorders,
most notably OCD and Tourette's syndrome. A large overlap in
comorbidity between these disorders as well as in the cognitive and
neural alterations, lead to the hypothesis that the standard categorical
disease classification for neurodevelopmental disorders may need to
be revisited, and that ADHD, ASD, OCD, and Tourette's syndrome
might actually lie on an impulsivity-compulsivity continuum, sharing
overlapping etiologies that converge in dysfunctional brain circuitries
(Clark, Cuthbert, Lewis-Fernández, Narrow, & Reed, 2017; Huisman-
van Dijk, van de Schoot, Rijkeboer, Mathews, & Cath, 2016). A major
next step in the ENIGMA consortium is the aim to unite multimodal
imaging comparisons across the neurodevelopmental disorder work-
ing groups, not only for ADHD and ASD, but also including ENIGMA-
OCD and Tourette's syndrome.
Additionally, for both ADHD and ASD it would be of great inter-
est to combine brain data from longitudinal samples. The previously
reported delay of maturation in ADHD, the absence of case–control
differences in the adult sub-analysis in ENIGMA-ADHD, or the
changes restricted to adolescence in ASD and the changes in the pre-
sentation of the disorders all support looking more closely and with
better data at the life-span perspective of brain changes related to
ADHD. Early biomarkers associated with ASD's development and
treatment outcome would additionally be of tremendous value to the
clinical community. Currently, and to this end, medium scale multicen-
ter longitudinal data are being collected as part of the EU-AIMS pro-
ject (Murphy & Spooren, 2012), which may offer a potential
collaboration partner for ENIGMA-ASD to investigate both longitudi-
nal structural brain analysis, but also includes extensive behavioral
phenotyping as well as EEG and eye-tracking data, which offers new
opportunities to link the ENIGMA imaging findings to a wider set of
behavioral and biological metrics.
The behaviors which are associated with both ADHD and ASD
are not unique to just a patient population, but exist as continuous
traits within the general population (Asherson & Trzaskowski, 2015;
HOOGMAN ET AL. 13
Bralten et al., 2018). This means that both the genetic and neuroimag-
ing features which are linked to ADHD and ASD may also be found as
distributed traits in population samples. Combining the results of the
ENIGMA analysis and the analysis of population-based brain data
have been successful in the case of ADHD cortical analyses
(Hoogman et al., 2019). We want to expand these types of analyses
because it gives us a better picture of brain characteristics across the
whole spectrum of these psychiatric traits.
Lastly, to combine genetic and neuroimaging data within
ENIGMA-ADHD and ASD, ideally one would need genetic and
imaging data from the same subjects to investigate which genetic
factors contribute to the brain characteristics that have been
found. Unfortunately, the samples in ENIGMA-ADHD and ASD are
still too small to conduct such analyses. However, combining data
from multiple large-scale databases of other collaborations has
shown that this also delivers new information, for example the pro-
ject about the genetic overlap of ADHD risk and genetic factors
involved in ADHD related brain volumes (Klein et al., 2019). In the
future we aim to perform more of these types of analyses and
encourage and invite other researchers to come up with interesting
hypotheses.
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